Fluid-sparing hyperoncotic albumin in severe dengue: A retrospective case series

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness and safety of early hyperoncotic albumin in patients with severe dengue shock syndrome (DSS) and hypoalbuminemia.
Retrospective analysis of patients with DSS from January 2022 to December 2025 at an ICU in Vietnam.
Included patients with confirmed dengue and severe hypoalbuminemia; excluded undocumented shock onset cases.
Categorized patients into three resuscitation strategies: crystalloid-only, early adjunct albumin, and rescue albumin.
Patients receiving early adjunct albumin exhibited a median shock reversal time of 6.3 hours.
100% survival rate with no severe respiratory failure events recorded.
The median total administered dose of hyperoncotic albumin in the first 24 hours was 0.41 g/kg.

We only have this paper's title and publication details.

Retrospective case series evaluates early hyperoncotic albumin in dengue shock syndrome, suggesting safety and benefits.

No takes yet. Share an insight, caveat, or question.

Le et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share